“Novel Small Molecules Targeting the Intrinsically Disordered Structural Ensemble of Alpha-Synuclein Protect Against Diverse Alpha-Synuclein Mediated Dysfunctions”

January 23, 2020 - Events
 class='attachment-visuel-actu wp-post-image'

Microarrays at NovAliX

Alzheimer’s has been the graveyard for so many would-be drugs.  Many big pharma companies have abandoned the race but despite that, there are smaller players with the chutzpah to engage.   Someone will succeed eventually. Could it be Cantabio?  A recent nature Scientific report from Cantabio scientists and NovAliX describes the identification of small molecules binders of alpha-Synuclein which is overexpressed and becomes aggregation in Parkinson’s disease. The data so far looks promising but there is still a long way to go.

The starting point for Cantabio’s drug discovery efforts came from NovAliX’s small-molecule microarray technology. This unique SPR based approach is ideally suited to unstable drug discovery targets.

Access to full article